Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IM-250
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IM-250 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Simplexvirus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : IM-250
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IM-250
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Life Sciences Partners
Deal Size : $23.7 million
Deal Type : Series A Financing
Innovative Molecules Raises €20 Million Series A Equity Financing Round
Details : The company will use the funds to advance its preclinical product candidate, IM-250, from the current late preclinical stage to a Phase 2 proof-of-concept study. IM-250 is a potent inhibitor of Herpes Simplex Virus type 1 (HSV-1) and type 2 (HSV-2) repli...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 07, 2021
Lead Product(s) : IM-250
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Life Sciences Partners
Deal Size : $23.7 million
Deal Type : Series A Financing
Reset All
